INFECTION BY CYTOMEGALOVIRUS IN PATIENTS WITH NEONATAL CHOLESTASIS

Nara Léia Gelle de OLIVEIRA3, Fernanda Rafful KANAWATY3, Sandra Cecilia Botelho COSTA2 and Gabriel HESSEL1

ABSTRACT – Background – Neonatal cholestasis syndrome with an intra or extrahepatic origin has been associated to viral infections. The participation of the cytomegalovirus in the etiopathogenesis of neonatal hepatitis has been already known for some time, but only recently there have been indications that this virus may be one of the possible etiologic factors for extrahepatic biliary atresia. 

Aims - To assess the prevalence of infection by cytomegalovirus in patients with intrahepatic cholestasis and extrahepatic cholestasis. To compare the clinical characteristics of the intrahepatic cholestasis and extrahepatic cholestasis groups with the cytomegalovirus serological results. 

Patients and Methods - This study consisted of 76 patients with neonatal cholestasis who were admitted between January 1980 and January 1999 when they underwent a cytomegalovirus serologic study using the ELISA method. A case note was kept on each patient with the following data: age of patient at admission, serologic result for cytomegalovirus, history of maternal infection, prematurity, fetal distress, birth weight, ponderal gain, choluria and fecal acholia. The final anatomic diagnosis of cholestasis was based on the results of an abdominal ultrasonography, a liver biopsy and its evolution. The patients were then divided into two groups: group I - intrahepatic cholestasis and group II – extrahepatic cholestasis. Each of these groups were then divided into two subgroups: subgroup A - positive serology (IgM) for cytomegalovirus and subgroup B – negative serology (IgM) for cytomegalovirus. Results - The frequency of positive serology (IgM) for cytomegalovirus in children with intrahepatic cholestasis was 29.4% and 28.5% in children with extrahepatic cholestasis. In comparison with group IIB, group IIA presented a higher rate of maternal infection history. The patients in group IIA demonstrated a delayed access to the service in comparison with group IA. The groups did not demonstrate any significant differences regarding the onset age of jaundice, choluria and fecal acholia, birth weight and ponderal gain. Conclusions - The positive (IgM) seroprevalence for cytomegalovirus in children with intrahepatic cholestasis and extrahepatic cholestasis is high. The history of maternal infection was more common in extrahepatic cholestasis patients with positive serology for cytomegalovirus. There was a delay in the referral of these patients which resulted in a late diagnosis and surgical treatment.

INTRODUCTION

The occurrence of neonatal cholestasis has been associated to congenital or acquired viral infections. Previous studies based on serologic tests indicated that the herpes group virus, especially cytomegalovirus (CMV) was implicated in the development of intrahepatic neonatal cholestasis(16). Infections due to CMV are present in about 1% to 2.4% of newborns in North America and in our country (5, 22, 26), but at the end of the first year of life, this very same infection is present in up to 60% of the children in the west(11, 12).

Intrauterine CMV transmission is due to primary or recurring maternal infections and it causes the greatest damages to the fetus when it occurs in the early pregnancy stages(6). However, the risk of fetal transmission seems greater when the maternal infection occurs during the final pregnancy trimester(13, 14, 20). The fetal infection may cause: the interruption of the pregnancy, prematurity, low birth weight in full term newborns and several congenital malformations such as inguinal hernia, cleft palate, dental abnormalities, polycystic kidneys, mitral and pulmonary stenosis, atrial and ventricular septal defects and atresia of the biliary ducts(7, 21).
The clinical symptoms of cytomegalovirus in full term neonates varies from an asymptomatic condition to a fully disseminated terminal condition. When the disease is clearly manifested in neonates they frequently show: jaundice, hemorrhagic suffusion, hepatosplenomegaly, microcephaly, chorioretinitis, deafness, and neuromuscular dysfunctions. The main laboratory findings are: anemia, thrombocytopenia, and periventricular calcification of the central nervous system\(^4\).

On the other hand, a perinatal infection occurs more frequently than a congenital infection, and the main source of infection is the maternal contact, either through cervical secretion during delivery or later through breast feeding, as the virus was found in both secretions obtained from seropositive CMV asymptomatic pregnant women\(^{9,10,18}\). A CMV perinatal infection usually presents an asymptomatic clinical development which appears as a cholestatic syndrome\(^{2,23}\).

Neonatal cholestatic syndrome may be a result of an intrahepatic or extrahepatic alterations. The etiologies of the intrahepatic group are included in one of the following subgroups: metabolic, toxic-medication, hereditary, anatomic and idiopathic infections. The main etiologies of the extrahepatic group are atresia of the extrahepatic biliary atresia (EHA) and choledochal cysts.

EHBA is the final result of a destructive inflammatory process that affects the intrahepatic and extrahepatic biliary ducts leading to fibrosis and obliteration of the biliary tract at some point between the porta hepatitis and the duodenum. The etiology of the disease is unknown, although there is a definite attractiveness in a hypothesis incriminating an in utero viral insult to the hepatobiliary system. The viruses studied in children with EHBA were reovirus type 3, rotavirus and CMV, but the results in relation to viral participation were controversial and inconclusive\(^1\).

Therefore, this study had the following aims: 1) to evaluate the prevalence of infection due to CMV in patients with intrahepatic cholestasis (IHC) and extrahepatic cholestasis (EHC); 2) to compare the clinical characteristics of the IHC and EHC groups with positive and negative serology for CMV.

### CASUISTIC AND METHODS

A retrospective study was conducted in 147 patients who were admitted with neonatal cholestasis to the Pediatric Gastroenterology Unit, University Hospital, Faculty of Medical Sciences, State University of Campinas (HC-UNICAMP), Campinas, SP, Brazil, between January 1980 and January 1999. A case note was kept on each of these patients with the following data: age of patient at admission; serologic result for CMV, IgG, and IgM; history of maternal infection; prematurity; fetal distress; birth weight; ponderal gain; jaundice; cholelithiasis and fecal acholia.

The age at onset was also noted for the last three items whenever they were present. After reporting all these items, 71 patients were excluded because they did not present serology for CMV \((n = 28)\) or the serological study did not differentiate between IgG and IgM \((n = 40)\) or even the results for IgM were doubtful during the first examination \((n = 3)\). At end there were 76 patients included in the study and they underwent serology for CMV using the ELISA method.

The final anatomic diagnosis of cholestasis was based on the results of an abdominal ultrasonography, a liver biopsy and the evolution. The patients were then divided into two groups: group I - IHC and group II – EHC. Each of these groups were then divided into two subgroups: subgroup A - positive serology (IgM) for CMV and subgroup B – negative serology (IgM) for CMV.

### Statistical analysis

Double entry tables were used to calculate the prevalence as well as to compare the categorical variables of the groups. The relationship between the variables was found out using the Chi-square test and the Exact Fisher test whenever necessary. The non-parametric Kruskal-Wallis test was used to compare the continuing variables. The level of significance adopted was \(P = 0.05\).

### RESULTS

Table 1 presents the number of IHC and EHC patients with a positive serology for CMV.

In the IHC group there were 29.4\% with positive serology for CMV and in the EHC group, 28.5\% with positive serology for CMV. This meant that there was no statistical significant difference.

Table 2 presents crossing of data: categorical variables, type of cholestasis and serological result for CMV.

The only variable that presented a statistical difference was the history of maternal infections.

Table 3 presents crossing of data: continuing variables, type of cholestasis and results of serology for CMV.

The only variable that demonstrated a significant statistical difference was the age (days) at the first consultation.

### DISCUSSION

The results of this study indicated a high prevalence of CMV in children with both intrahepatic and extrahepatic neonatal cholestasis. It has been already known for sometime that this virus is a participant in the etiopathogenesis of neonatal hepatitis\(^{16,17}\), but only recently it has been indicated as a possible etiologic factor in EHB A\(^{4,24}\).
TABLE 1 – Results of serology (IgM positive) for cytomegalovirus in group I (IHC) and in group II (EHC)

<table>
<thead>
<tr>
<th>Group</th>
<th>CMV negative</th>
<th>CMV positive</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>24</td>
<td>10</td>
<td>34</td>
</tr>
<tr>
<td>II</td>
<td>30</td>
<td>12</td>
<td>42</td>
</tr>
<tr>
<td>Total</td>
<td>54</td>
<td>22</td>
<td>76</td>
</tr>
</tbody>
</table>

TABLE 2 – Results in percentage of some of the categorical variables studied in children with neonatal cholestasis. Group IA = IHC and positive serology for CMV; group IB = IHC and negative serology for CMV; group IIA = EHC and positive serology for CMV and group IIB = EHC and negative serology for CMV. The value of $P$ is for the following comparisons: IA x IIA; IB x IIB; IA x IB and IIA x IIB

<table>
<thead>
<tr>
<th>Items studied</th>
<th>Group IA</th>
<th>Group IB</th>
<th>Group IIA</th>
<th>Group IIB</th>
<th>Value of $P$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Choluria</td>
<td>80,00</td>
<td>86,96</td>
<td>83,33</td>
<td>92,86</td>
<td>&gt;0,05</td>
</tr>
<tr>
<td>Fecal Acholia</td>
<td>70,00</td>
<td>82,61</td>
<td>100,00</td>
<td>90,00</td>
<td>&gt;0,05</td>
</tr>
<tr>
<td>History of maternal infections</td>
<td>22,22</td>
<td>22,22</td>
<td>41,67</td>
<td>8,70</td>
<td>&lt;0,05 IA x IIB</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Others</td>
</tr>
<tr>
<td>Full term birth</td>
<td>50,00</td>
<td>59,09</td>
<td>91,67</td>
<td>78,57</td>
<td>&gt;0,05</td>
</tr>
<tr>
<td>Fetal distress</td>
<td>33,33</td>
<td>14,29</td>
<td>0,00</td>
<td>8,33</td>
<td>&gt;0,05</td>
</tr>
</tbody>
</table>

TABLE 3 – The results of the mean and median (showed between parenthesis) of some of the continuing variables studied in children with neonatal cholestasis. Group IA = IHC and positive serology for CMV; group IB = IHC and negative serology for CMV; group IIA = EHC and positive serology for CMV and group IIB = EHC and negative serology for CMV. The value of $P$ is for the following comparisons: IA x IIA; IB x IIB; IA x IB e IIA x IIB

<table>
<thead>
<tr>
<th>Items studied</th>
<th>Group IA</th>
<th>Group IB</th>
<th>Group IIA</th>
<th>Group IIB</th>
<th>Value of $P$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (days) at the 1º consultation</td>
<td>63.60</td>
<td>66.56</td>
<td>109.16</td>
<td>91.16</td>
<td>IA x IIA&lt;0.05</td>
</tr>
<tr>
<td></td>
<td>(58.00)</td>
<td>(54.00)</td>
<td>(109.00)</td>
<td>(77.00)</td>
<td>Others&gt;0.05</td>
</tr>
<tr>
<td>Age at onset of jaundice (days)</td>
<td>19.20</td>
<td>20.43</td>
<td>3.16</td>
<td>12.07</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td></td>
<td>(7.00)</td>
<td>(7.00)</td>
<td>(1.00)</td>
<td>(3.00)</td>
<td></td>
</tr>
<tr>
<td>Age at onset of choluria (days)</td>
<td>35.25</td>
<td>16.09</td>
<td>36.00</td>
<td>11.04</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td></td>
<td>(31.00)</td>
<td>(2.00)</td>
<td>(15.00)</td>
<td>(5.00)</td>
<td></td>
</tr>
<tr>
<td>Age at onset of acholia (days)</td>
<td>36.57</td>
<td>29.00</td>
<td>37.20</td>
<td>14.86</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td></td>
<td>(36.00)</td>
<td>(30.00)</td>
<td>(26.00)</td>
<td>(6.50)</td>
<td></td>
</tr>
<tr>
<td>Birth weight (gm)</td>
<td>2884.00</td>
<td>2938.00</td>
<td>3228.00</td>
<td>3171.50</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td></td>
<td>(3160.00)</td>
<td>(2932.50)</td>
<td>(3140.00)</td>
<td>(3065.00)</td>
<td></td>
</tr>
<tr>
<td>Ponderal gain (gm/day)</td>
<td>20.17</td>
<td>19.69</td>
<td>17.95</td>
<td>14.52</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td></td>
<td>(22.37)</td>
<td>(20.96)</td>
<td>(19.10)</td>
<td>(12.69)</td>
<td></td>
</tr>
</tbody>
</table>
CHANG et al.\(^{(3)}\), used the polymerase chain reaction (PCR) to study CMV in liver tissue of children with neonatal cholestasis and it was found that out of 50 children with IHC, 23 children were positive and in 26 children with EHBA, only 2 were positive. JEVON and DIMMICK\(^{(8)}\), had similar results. They did not find any patient with CMV among the 12 children with EHBA who were studied using PCR in the liver tissue.

FISCHLER et al.\(^{(4)}\), on the other hand, studied 59 children with neonatal cholestasis and found that 32% presented IgM-CMV, while 6% of the children in the control group (without cholestasis) were positive. This positive percentage included, both, children with IHC (11 out of 38) as well as children with EHBA (8 out of 21). When these authors used the PCR to study this virus in the liver tissue, the number of children found to be positive was much higher: 50% prevalence (9 out of 18) in children with EHBA; 42.8% (3 out of 7) in children with other types of cholestasis. These diverging results may be due to the difference in the prevalence of this virus in the general population or a difference in the CMV infecting strain.

The detection of a specific IgM-CMV after the 4th week of life may be a consequence of a congenital or perinatal infection. Previous studies made in Brazil had shown that a positive prevalence of IgM to CMV between the 2nd and the 4th month of life varies from 8.1% to 14.7%. Therefore, when it is putting along with the detection method of CMV at the urine by viral isolation in cultured cells, this prevalence of the infection increases about from 30.9% to 38%, being asymptomatic in the great majority of cases.\(^{(13, 25)}\) Based on these results, it would be interesting the inclusion of a control group of children without neonatal cholestasis, with an equivalent age group, although it was not possible due to the fact that it is a retrospective study. So, the presence of a specific IgM to CMV only suggests that this virus may be the etiologic agent of the neonatal cholestasis syndrome but it does not confirm it.

An analysis of some of the categorical variables showed that regarding the history of maternal infection variable, there was a significant difference between the subgroups IIA and IIB. In these subgroups, the serology was also negative for other infectious agents routinely studied: syphilis, toxoplasmosis, rubella and hepatitis B. It is likely that a significant percentage of mothers with IgM-CMV children with EHBA presented a reactivation of the disease during pregnancy. This hypothesis is based on the study conducted by FISCHLER et al.\(^{(4)}\), who observed a greater proportion of seropositive mothers (IgG for CMV) in the group of children with neonatal cholestasis than in the control group, and in the same way, a greater percentage of these mothers demonstrated an increased IgG for CMV.

After analyzing some continuing variables, no difference was observed between the subgroups regarding onset age for jaundice, choluria, and fecal acholia. Similarly, no difference was observed between the subgroups regarding birth weight and ponderal gain. On the other hand, a difference was observed between the subgroups IA and IIA regarding the age at the first consultation at the Pediatric Gastroenterology Unit, HC-UNICAMP, which meant a delayed referral for the subgroup with EHBA and positive serology for CMV. The following report found at the case notes of the subgroup IIA patients is common: mother brought the child to the doctor complaining of jaundice and several investigations were requested by the physician. The results confirmed that the hepatitis was viral and therefore it was needed a period of resting. The jaundice worsened and the child was referred to the Pediatric Gastroenterological Unit, HC-UNICAMP where the final anatomic diagnosis was EHBA. The treatment recommended for this disease is surgical and should be performed as early as possible and the ideal timing is before the age of 2 months. As seen in this study, the mean and median age at which the child was brought to this service was approximately 3\(\frac{1}{2}\) months and in most cases the delay for referral was definitely because the results showed a positive serology (IgM) for cytomegalovirus. Hence, in many cases the patient missed the opportunity of undergoing a surgery to restore the biliary flow or when the surgery was performed, the results were usually unsatisfactory.

In conclusion, in children with IHC and EHC, the positive (IgM) seroprevalence for CMV was high. The virus in the liver tissue is being investigated using PCR in our laboratory to find out the actual prevalence and etiopathogenic participation of this virus in neonatal cholestasis. The presence of positive IgM serology for CMV must not interrupt the procedures used to differentiate IHC from EHC.
RESUMO – Racional – A síndrome colestática neonatal, de origem intra ou extra-hepática, tem sido associada à presença de infeções virais. A participação do citomegalovírus na etiopatogênese da hepatite neonatal já é conhecida há algum tempo e só recentemente esse vírus tem sido implicado como dos possíveis fatores etiológicos da atresia de vias biliares extra-hepática. Objetivos – Calcular a prevalência da infecção pelo citomegalovírus em pacientes com colestease intra-hepática e colestease extra-hepática e comparar algumas características clínicas entre os grupos de colestease intra-hepática e colestease extra-hepática com o resultado de sorologia para citomegalovírus. Casuística e Métodos – Participaram do estudo 76 pacientes com colestease neonatal admitidos durante o período de janeiro de 1980 a janeiro de 1999 que realizaram pesquisa sorológica para citomegalovírus pelo método ELISA. Para todos esses pacientes foi elaborada uma ficha contendo os seguintes dados: idade do paciente na admissão, resultado de sorologia para citomegalovírus, história de infecção materna, prematuridade, solfrimento fetal, peso de nascimento, gângio ponderal, colúria e acolia fecal. O diagnóstico anatômico final da colestease fundamentou-se no resultado de ultrasonografia abdominal, biópsia hepática e evolução. Dessa forma, os pacientes foram divididos em dois grupos: I - colestease intra-hepática e II - colestease extra-hepática. Cada um desses grupos foi dividido em dois subgrupos: A - com sorologia positiva (IgM) para citomegalovírus e B - com sorologia negativa (IgM) para citomegalovírus. Resultados – A prevalência observada de sorologia positiva (IgM) para citomegalovírus nas crianças com colestease intra-hepática e colestease extra-hepática foi de 29,4% e 28,5%, respectivamente. O grupo IIA apresentou percentual maior de história de infecção materna quando comparado ao grupo IIB. Os pacientes do grupo IIA apresentaram acesso mais tardio ao Serviço em relação àqueles do grupo IA. Não foram observadas diferenças significativas entre os grupos em relação à idade de início da icterícia, colúria e acolia fecal, bem como em relação ao peso de nascimento e ganho ponderal. Conclusão – A prevalência de sorologia positiva (IgM) para citomegalovírus em crianças com colestease intra-hepática e colestease extra-hepática é alta. A história de infecção materna é mais comum nos pacientes com colestease extra-hepática e sorologia positiva para citomegalovírus. Nesses pacientes, o encaminhamento foi mais tardio com atraso no diagnóstico e no tratamento cirúrgico.


REFERENCES